Although we have demonstrated that pharmacological inhibition of MST1/2 can impede ER+ breast cancer growth in vivo, the subcutaneous xenograft model employed in our study requires supraphysiological concentrations of estrogen and thus may compromise clinical relevance. The gene discussed is ESR1; the disease is breast carcinoma.